呋喹替尼在晚期结直肠癌中的研究进展  

Research Progress of Fruquintinib on Advanced Colorectal Cancer

作　　者：孙利英 毛野 黄志群 黄胜兰 李丹 吴建兵[1] SUN Liying;MAO Ye;HUANG Zhiqun;HUANG Shenglan;LI Dan;WU Jianbing(Department of Oncology,The Second Affiliated Hospital of Nanchang University,Nanchang 360000,China;Department of Otorhinolaryngology Head and Neck Surgery,Affiliated Hospital of Jiujiang University,Jiujiang 332000,China)

机构地区：[1]南昌大学第二附属医院肿瘤科,南昌360000 [2]九江学院附属医院耳鼻咽喉头颈外科,九江332000

出　　处：《肿瘤防治研究》2021年第12期1135-1142,共8页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金(82060435);江西省自然科学基金(S2020ZRMSB0396)。

摘　　要：呋喹替尼是一种有效的、高选择性和口服VEGFR 1、2、3酪氨酸激酶抑制剂,由Hutchison MediPharma发现并开发用于治疗实体肿瘤。2018年9月,呋喹替尼在中国获得全球首个批准,用于接受至少两种系统性抗肿瘤治疗失败的转移性结直肠癌患者治疗。临床研究表明,它具有脱靶毒性低、耐药性好、疗效强等优点。本文综述了呋喹替尼的分子结构、作用机制、药代动力学、临床疗效和安全性,并讨论了其在其他肿瘤类型中的潜在临床应用。Fruquintinib is an effective,highly selective and oral VEGFR 1,2 and 3 tyrosine kinase inhibitor.It was discovered and developed by Hutchison MediPharma for the treatment of solid tumors.In September 2018,fruquintinib received its first global approval in China for use in the treatment of metastatic colorectal cancer(CRC)patients who have failed at least two prior systemic anti-neoplastic therapies.Clinical studies have shown that it has the advantages of low off-target toxicity,good drug resistance and strong curative effect.This article reviews the molecular structure,mechanism of action,pharmacokinetics,clinical efficacy and safety of fruquintinib,as well as its potential clinical applications in other tumor types.

关 键 词：呋喹替尼 抗血管生成药物 结直肠癌 

分 类 号：R735.34[医药卫生—肿瘤]